CClinicalTrials.gg
Sign In
CompletedNCT00889031Updated Apr 7, 2020

Protocol to Obtain Blood Samples for Leukemia Research

An observational study in Chronic Lymphocytic Leukemia, sponsored by Dartmouth-Hitchcock Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-07.

Sponsored by Dartmouth-Hitchcock Medical Center · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
187
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to collect a blood sample in patients with Chronic Lymphocytic Leukemia (CLL).

Read the detailed description

The blood sample will be used in the laboratory to perform studies focusing on Chronic Lymphocytic Leukemia (CLL).

02

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • CLL
03

In context

Leukemia

5,441 studies on the registry are indexed under Leukemia; 636 are open to participants now.

This study's enrollment of 187 is above the median of 120 across 744 observational studies indexed under Leukemia.

Browse Leukemia studies →

Lead sponsor

Dartmouth-Hitchcock Medical Center is the lead sponsor of 472 studies on the registry; 68 are open to participants now.

Of its 30 completed or terminated interventional studies of FDA-regulated products, 20 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients at Dartmouth-Hitchcock Medical Center's Norris Cotton Cancer Center

Inclusion criteria

  • Patients undergoing routine blood draws as part of their ongoing follow-up for Chronic Lymphocytic Leukemia (CLL) at the Norris Cotton Cancer Center of DHMC.

Exclusion criteria

Exclusion Criteria:

  • Patients who have received cytotoxic drug, oral or intravenous steroid or targeted antibody therapy for CLL or other disease process within the past 6 months are excluded. Use of intravenous immunoglobulin (IVIg) is not a reason for exclusion.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
187 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • No Treatment

    Other: No Intervention

Interventions

  • OtherNo Intervention

    Patients with Chronic Lymphocytic Leukemia (CLL)

06

What researchers measure

Primary outcomes

  1. To determine the frequency with which CLL cells incubated ex vivo with vincristine undergo rapid interphase apoptosis.

    Time frame: 2 Years

Secondary outcomes

  1. To determine whether suppression or inhibition of BCL2 family members can acutely sensitize CLL cells to vincristine.

    Time frame: 2 Years

07

Study locations

1 site
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
08

References and documents

Publications

  • Stadheim TA, Xiao H, Eastman A. Inhibition of extracellular signal-regulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine-treated ML-1 cells. Cancer Res. 2001 Feb 15;61(4):1533-40. PubMed 11245462 ↗
  • Vilpo JA, Koski T, Vilpo LM. Selective toxicity of vincristine against chronic lymphocytic leukemia cells in vitro. Eur J Haematol. 2000 Dec;65(6):370-8. doi: 10.1034/j.1600-0609.2000.065006370.x. PubMed 11168494 ↗
  • Kivekas I, Vilpo L, Vilpo J. Relationships of in vitro sensitivities tested with nine drugs and two types of irradiation in chronic lymphocytic leukemia. Leuk Res. 2002 Nov;26(11):1035-41. doi: 10.1016/s0145-2126(02)00050-4. PubMed 12363473 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00889031
Lead sponsor
Dartmouth-Hitchcock Medical Center
Responsible party
Christopher H. Lowrey (Professor of Medicine and of Pharmacology and Toxicology, Dartmouth-Hitchcock Medical Center) — Principal investigator
First posted
Apr 28, 2009
Start date
Apr 2009
Primary completion
Mar 9, 2018
Completion
Mar 9, 2018
Last update
Apr 7, 2020

Study contacts

Christopher H Lowrey, MD
principal investigator · Dartmouth-Hitchcock Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Leukemia→

Other studies from this sponsor

Dartmouth-Hitchcock Medical Center

Start the discussion